These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. van Vark LC; Lesman-Leegte I; Baart SJ; Postmus D; Pinto YM; Orsel JG; Westenbrink BD; Brunner-la Rocca HP; van Miltenburg AJM; Boersma E; Hillege HL; Akkerhuis KM; J Am Coll Cardiol; 2017 Nov; 70(19):2378-2388. PubMed ID: 29096809 [TBL] [Abstract][Full Text] [Related]
29. Biomarkers: Their potential in the diagnosis and treatment of heart failure. Heil B; Tang WH Cleve Clin J Med; 2015 Dec; 82(12 Suppl 2):S28-35. PubMed ID: 26694889 [TBL] [Abstract][Full Text] [Related]
30. Biomarkers shared by frailty and sarcopenia in older adults: A systematic review and meta-analysis. Picca A; Coelho-Junior HJ; Calvani R; Marzetti E; Vetrano DL Ageing Res Rev; 2022 Jan; 73():101530. PubMed ID: 34839041 [TBL] [Abstract][Full Text] [Related]
31. [Soluble ST2 - as a biomarker, a tool for risk stratification and therapeutic target in patients with chronic heart failure]. Kamardinov DK; Songurov RN; Ioshina VI; Buziashvili YI Kardiologiia; 2019 Nov; 60(2):111-121. PubMed ID: 32345207 [TBL] [Abstract][Full Text] [Related]
32. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. Ahmad T; Fiuzat M; Neely B; Neely ML; Pencina MJ; Kraus WE; Zannad F; Whellan DJ; Donahue MP; Piña IL; Adams KF; Kitzman DW; O'Connor CM; Felker GM JACC Heart Fail; 2014 Jun; 2(3):260-8. PubMed ID: 24952693 [TBL] [Abstract][Full Text] [Related]
33. Biomarkers for heart failure: small molecules with high clinical relevance. Magnussen C; Blankenberg S J Intern Med; 2018 Jun; 283(6):530-543. PubMed ID: 29682806 [TBL] [Abstract][Full Text] [Related]
35. The challenge of frailty and sarcopenia in heart failure with preserved ejection fraction. Kinugasa Y; Yamamoto K Heart; 2017 Feb; 103(3):184-189. PubMed ID: 27940967 [TBL] [Abstract][Full Text] [Related]
36. Current and novel biomarkers in heart failure: bench to bedside. Ghashghaei R; Arbit B; Maisel AS Curr Opin Cardiol; 2016 Mar; 31(2):191-5. PubMed ID: 26814650 [TBL] [Abstract][Full Text] [Related]
37. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure. Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907 [TBL] [Abstract][Full Text] [Related]
38. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Zile MR; Jhund PS; Baicu CF; Claggett BL; Pieske B; Voors AA; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD; Circ Heart Fail; 2016 Jan; 9(1):. PubMed ID: 26754625 [TBL] [Abstract][Full Text] [Related]
39. Galectin-3 and heart failure: prognosis, prediction & clinical utility. Filipe MD; Meijers WC; Rogier van der Velde A; de Boer RA Clin Chim Acta; 2015 Mar; 443():48-56. PubMed ID: 25446877 [TBL] [Abstract][Full Text] [Related]
40. Multisystem derangements in frailty and sarcopenia: a source for biomarker discovery. Picca A; Calvani R; Marzetti E Curr Opin Clin Nutr Metab Care; 2022 May; 25(3):173-177. PubMed ID: 35238804 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]